Company / Capital Returned to Shareholders per Share
Bristol Myers Squibb Capital Returned to Shareholders per Share History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Capital Returned to Shareholders per Share
$2.43
FY2025
5-year range
$2.27 / $5.83
FY2021-FY2025
Trend
+7.1%
vs FY2024
Sector context
#12 of 51
Health Care
What the data says
Bristol Myers Squibb's capital returned to shareholders per share of $2.43 is higher than 76% of companies in the Health Care sector (FY2025). Capital Returned to Shareholders per Share has fluctuated over the past 10 years, ranging from $1.57 in FY2016 to $5.83 in FY2021.
Based on SEC 10-K filings.
2.43 in FY2025 with a 5-year CAGR of -6.7%. Top quartile in the Health Care sector.
Declined from $4.76 to $2.43 over the past 2 years.
Health Care sector context is included.
Capital Returned to Shareholders per Share over time
Growth rates
- 3-Year CAGR
- -0.8%
- 5-Year CAGR
- -6.7%
- 10-Year CAGR
- -
Sector benchmark
-11.2% below sector average
Key checks
Key Insights
- In FY2025, capital returned to shareholders per share increased 7.1% year-over-year.
- Ranks #12 out of 51 companies in the Health Care sector.
- Peak capital returned to shareholders per share was recorded in FY2021.
- Lowest capital returned to shareholders per share in the period was in FY2016.
Company context
Key Data Points
- High Piotroski F-Score: 8/9 (strong financial health signals)
- Altman Z-Score 0.85 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
- Strong return on equity: 32.6%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Capital Returned to Shareholders per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $2.43 | +7.1% |
| FY2024 | $2.27 | -52.4% |
| FY2023 | $4.76 | +91.2% |
| FY2022 | $2.49 | -57.3% |
| FY2021 | $5.83 | +69.8% |
| FY2020 | $3.43 | +12.4% |
| FY2019 | $3.05 | +84.7% |
| FY2018 | $1.65 | -45.0% |
| FY2017 | $3.01 | +90.9% |
| FY2016 | $1.57 | -4.6% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026